NASDAQ:ALVO - Nasdaq - LU2458332611 - Common Stock - Currency: USD
8.36
0 (0%)
The current stock price of ALVO is 8.36 USD. In the past month the price decreased by -28.3%. In the past year, price decreased by -40.92%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.5 | 313.20B | ||
AMGN | AMGEN INC | 14.02 | 149.41B | ||
GILD | GILEAD SCIENCES INC | 23.08 | 132.62B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1698 | 126.59B | ||
REGN | REGENERON PHARMACEUTICALS | 12.88 | 64.26B | ||
ARGX | ARGENX SE - ADR | 319.7 | 36.31B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.48B | ||
BNTX | BIONTECH SE-ADR | N/A | 27.60B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.85B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 24.51B | ||
NTRA | NATERA INC | N/A | 20.08B | ||
BIIB | BIOGEN INC | 7.17 | 17.30B |
Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focused on the development and manufacture of biosimilar medicines for patients globally. The company is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). The company has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
ALVOTECH SA
9, Rue De Bitbourg
Luxembourg LU
Employees: 999
Company Website: https://www.alvotech.com/
Investor Relations: http://investors.alvotech.com/
Phone: 35244224500
The current stock price of ALVO is 8.36 USD.
The exchange symbol of ALVOTECH SA is ALVO and it is listed on the Nasdaq exchange.
ALVO stock is listed on the Nasdaq exchange.
10 analysts have analysed ALVO and the average price target is 18.87 USD. This implies a price increase of 125.72% is expected in the next year compared to the current price of 8.36. Check the ALVOTECH SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ALVOTECH SA (ALVO) has a market capitalization of 2.52B USD. This makes ALVO a Mid Cap stock.
ALVOTECH SA (ALVO) currently has 999 employees.
ALVOTECH SA (ALVO) has a support level at 8.28 and a resistance level at 8.8. Check the full technical report for a detailed analysis of ALVO support and resistance levels.
The Revenue of ALVOTECH SA (ALVO) is expected to grow by 42.14% in the next year. Check the estimates tab for more information on the ALVO EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALVO does not pay a dividend.
ALVOTECH SA (ALVO) will report earnings on 2025-05-07, after the market close.
ALVOTECH SA (ALVO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.87).
The outstanding short interest for ALVOTECH SA (ALVO) is 0.5% of its float. Check the ownership tab for more information on the ALVO short interest.
ChartMill assigns a fundamental rating of 4 / 10 to ALVO. Both the profitability and financial health of ALVO have multiple concerns.
Over the last trailing twelve months ALVO reported a non-GAAP Earnings per Share(EPS) of -0.87. The EPS increased by 64.39% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -18.98% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 78% to ALVO. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 104.4% and a revenue growth 42.14% for ALVO